Skip to main content
. 2024 May 15;8(14):3721–3730. doi: 10.1182/bloodadvances.2023012539

Table 2.

Best responses to therapy

VCD (n = 57)
VCDD (n = 64)
P value
% 95% CI % 95% CI
OR (PR or better) 64.91 51.13-77.09 85.94 74.98-93.36 .007
CR/sCR 3.51 0.43-12.11 6.25 1.73-15.24 .488
≥VGPR 28.07 16.97-41.54 51.56 38.73-64.25 .009
MR 10.53 3.96-21.52 6.25 1.73-15.24 .394
SD 12.28 5.08-23.68 0.00 0.00-5.60 .004
PD 1.75 0.04-9.39 0.00 0.00-5.60 .287
MRD-negative 5.26 1.10-14.62 15.63 7.76-26.86 .066

MR, minimal response; PD, progressive disease; SD, stable disease.

Patients not known to be MRD-negative, with a missing value, either through a missing or suboptimal sample, are assumed to be MRD-positive.